TIDMAMP

RNS Number : 7576Z

Amphion Innovations PLC

05 September 2018

Amphion Innovations plc

("Amphion" or "the Company")

Board Change

London and New York: 5 September 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses announces the appointment of Stephen Austin as an additional non-executive director effective immediately. Following a career as a corporate lawyer, qualified executive and corporate stockbroker, Stephen is now the Chief Investment Officer of Plumtree Capital Limited, an FCA authorised corporate finance firm.

Stephen will join the Compensation Committee (as chairman) and the Audit Committee.

Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.

Stephen Michael Austin (age 51) is, or has been in the previous five years, a director or partner, of the following companies:

 
 Current appointments             Past appointments 
 EC Aquisitions plc               Wisdom Acquisitions plc 
 Plumtree Capital Limited 
 Plumtree Opportunities Limited 
 Plumtree Small Cap Credit LLP

Stephen Austin currently owns 300,000 warrants in the Company. The warrants have an exercise price of 3.5 pence and expire 28 July 2019.

Richard Morgan, CEO, commented: "We have worked with Stephen for four years on a range of projects including the successful AIM IPOs of Motif Bio and Polarean Imaging and now welcome him to the Board."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information please contact:

 
 Amphion Innovations                                            Tel: +1 (212) 210 6224 
 Charlie Morgan 
 
 Panmure Gordon Limited (Nominated Adviser                         Tel: +44 (0)20 7886 
  and Corporate Broker)                                                           2500 
 Freddy Crossley / Emma Earl (Corporate 
  Finance) 
 Charlie Leigh-Pemberton (Corporate 
  Broking) 
 
 Northland Capital Partners Limited (Joint                         Tel: +44 (0)20 3861 
  Corporate Broker)                                                               6625 
 David Hignell (Corporate Finance) 
 Vadim Alexandre (Corporate Broking) 
 
 Walbrook PR                        Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com 
 Anna Dunphy / Paul 
  McManus

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

On the web: www.amphionplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAFKQDQPBKDACK

(END) Dow Jones Newswires

September 05, 2018 02:01 ET (06:01 GMT)

Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Amphion Innovations Charts.
Amphion Innovations (LSE:AMP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Amphion Innovations Charts.